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G astric cancer is one of the leading causes of can-cer-related death worldwide [1].  Combination 
therapy with fluoropyrimidine and a platinum agent is 
used as the first-line treatment for unresectable or 
recurrent gastric cancer [2],  and the survival benefits 
conferred by several second-line regimens have been 
demonstrated in randomized trials [3-5].  Patients 
treated with weekly solvent-based paclitaxel (sb-PTX) 
showed overall survival (OS) rates similar to those of 
patients treated with irinotecan [6],  and the 
RAINBOW trial demonstrated the superiority of ramu-
cirumab (RAM) plus weekly sb-PTX over weekly 
sb-PTX alone as a second-line regimen [7].  Therefore,  
RAM plus weekly sb-PTX is now recommended as a 
second-line treatment in the 2018 Japanese gastric can-
cer treatment guidelines (5th edition) [8].
Nanoparticle albumin-bound paclitaxel (nab-PTX) 
is a solvent-free,  albumin-bound 130-nm particle form 
of PTX that carries a reduced risk of polyethoxylated 
castor oil-associated hypersensitivity reactions and does 
not require the use of hydrated ethanol as a solvent [9].  
The non-inferiority of weekly nab-PTX compared to 
weekly sb-PTX was demonstrated in the ABSOLUTE 
trial [10],  and the safety and efficacy of RAM plus 
weekly nab-PTX were shown in a phase II trial [11].  
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As the nanoparticle albumin-bound paclitaxel (nab-PTX) is free of ethanol and premedication,  the duration of 
administration is shorter and patients can drive themselves to and from the hospital.  In the 2018 Japanese gas-
tric cancer treatment guidelines,  ramucirumab (RAM) plus weekly nab-PTX is conditionally recommended for 
previously treated patients with advanced gastric cancer.  Here,  we retrospectively analysed the efficacy and 
safety of RAM+nab-PTX for such patients in community hospitals.  From January 2018 to December 2019,  43 
patients with metastatic and recurrent gastric cancer received RAM+nab-PTX treatment.  Six patients (13.9%) 
were older than 80 years and 9 patients (20.9%) showed ECOG-PS 2.  Progression-free survival (PFS),  overall 
survival (OS),  overall response rate (ORR),  disease control rate (DCR),  and adverse events (AEs) were 
reviewed retrospectively.  Median PFS was 114 days (95% confidence interval [CI]: 84-190) and median OS was 
297 days (95% CI: 180-398).  ORR and DCR were 32.4% and 72.2%,  respectively.  The incidence rates of 
≥ grade 3 neutropenia and febrile neutropenia were 53.5% and 2.3%,  respectively.  No treatment-related deaths 
occurred.  RAM plus nab-PTX combination therapy demonstrated manageable toxicity even patients who were 
elderly or had an ECOG-PS 2.  This treatment is useful in community hospital settings.
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Therefore,  RAM plus weekly nab-PTX (RAM+nab-
PTX) is conditionally recommended as a second-line 
chemotherapy regimen in the 2018 Japanese gastric 
cancer treatment guidelines (5th edition) [2].  As this 
regimen is ethanol-free and does not require premedi-
cation,  it is particularly appropriate for use in rural 
settings.  Accordingly,  RAM+nab-PTX has been in use 
at our hospital since 2018.  In this study,  we retrospec-
tively analyzed the efficacy and safety of RAM+nab-
PTX in previously treated patients with advanced gas-
tric cancer in a community hospital.
Patients and Methods
Patients. Between January 2018 and December 
2019,  we used RAM+nab-PTX as a second-line chemo-
therapy to treat patients with metastatic or recurrent 
gastric cancer with histologically confirmed adenocar-
cinoma.  RAM+nab-PTX treatment was prescribed by 
the attending doctor,  according to the Eastern 
Cooperative Oncology Group (ECOG) performance 
status (PS),  basal disease,  and the patient’s consent.  
Patients were excluded if their ECOG-PS was 3 or 4,  or 
if they had inadequate bone marrow,  or hepatic or renal 
function.  Patients with a history of thromboembolism 
were included if they were anticoagulated.  Age and 
previous treatment regimen were not considered.  
General consent was obtained before treatment,  and 
individual consent to participate in this study was 
obtained from each subject after approval of the study 
design by the ethics review board of our institution.
Treatment. Patients received nab-PTX (100 mg/
m2) on days 1,  8,  and 15,  and RAM (8 mg/kg) on days 
1 and 15 of a 28-day cycle.  The criteria for treatment 
were based on the JapicCTI-153088 trial [11],  with 
modifications made by the attending doctor as required.  
Treatment was continued until disease progression,  
deterioration of general condition,  unacceptable toxic-
ity,  or the patient wished to stop treatment.
Patient evaluation. Physical examination and 
blood laboratory tests were conducted before every drug 
administration,  and computed tomography (CT) scans 
were performed every 2-3 cycles.  We retrospectively 
reviewed clinical records regarding patient characteris-
tics,  dosage,  schedule,  relative dose intensity (RDI),  
adverse events (AEs),  tumor response,  progression- 
free survival (PFS),  and overall survival (OS).  AEs 
were evaluated according to the Common Terminology 
Criteria for Adverse Events (ver. 4) [11].  Measurable 
solid tumors were evaluated according to the Response 
Evaluation Criteria in Solid Tumors (RECIST) [12].  In 
the absence of measurable tumors,  the volume of asci-
tes or pleural effusion,  tumor markers (carcinoembry-
onic antigen [CEA] and carbohydrate antigen [CA] 
19-9) were evaluated,  according to the radiologist and 
attending doctor’s diagnosis.
Statistical methods. PFS and OS were analyzed 
using the Kaplan-Meier method,  and JMP ver. 10.0.2 
(SAS Institute,  Cary,  NC,  USA) was used for statistical 
analysis.
Results
Patient characteristics. Forty-three patients 
received RAM+nab-PTX treatment at our institution.  
Patient characteristics are shown in Table 1.  The 
median age was 70 years,  with 34 patients (79.1%) older 
than 65,  and 6 (14%) older than 80.  Nine patients had 
ECOG-PS 2 (20.9%).  Measurable tumors were present 
in 29 cases,  while 14 cases had none.  Previous chemo-
therapy regimens are shown in Table 1.
Treatment. The median number of cycles was 3 
(range: 1-11).  The regimen was discontinued during 
the first cycle in 7 cases.  The average RDIs of nab-PTX 
and RAM were 59.4% (range: 25.9-100.0%) and 80.2% 
(range: 14.3-100.0%),  respectively.  The average total 
doses of nab-PTX and RAM were 1,041.0 mg (range:  
100-2,350 mg) and 3,724.4 mg (range: 250-8,600 mg),  
respectively (Table 2).
Efficacy. The median PFS was 114 days (95% 
confidence interval [CI]: 84-190) and the median OS 
was 297 days (95% CI: 180-398) (Fig. 1).  Treatment 
was discontinued before efficacy evaluation in 6 cases,  
which were therefore disregarded in this assessment.  
The overall response rate (ORR) and disease control rate 
(DCR) were 32.4% and 70.2%,  respectively (Table 2).  
Of the 37 assessed patients,  4 showed complete 
response; 8,  partial response; 14,  stable disease; and 
11,  progressive disease.
In patients with measurable tumors,  the ORR and 
DCR were 32.0% and 64.0%,  respectively.  In patients 
without measurable tumors,  the ORR and DCR were 
33.3% and 83.3%,  respectively.  Additionally,  there was 
reduced massive pleural effusion or reduced ascites in 4 
of 9 cases (44.4%).
AEs. Treatment-related AEs are listed in Table 3.  
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Given that AEs were evaluated retrospectively using 
clinical records,  several subjective AEs may have been 
missed.
There were no infusion reactions.  Although ≥ grade 
3 neutropenia occurred in 23 cases (53.5%) and grade 4 
neutropenia occurred in 14 cases (32.6%),  febrile neu-
tropenia occurred in only one case (2.3%).  The patient 
who experienced grade 3 febrile neutropenia recovered 
with antibiotic treatment and was able to continue 
receiving the chemotherapy regimen.  Treatment was 
discontinued in 2 cases,  1 each due to grade 3 neutro-
penia and grade 2 peripheral neuropathy.  No treat-
ment-related deaths occurred.
Post-treatment follow-up. Treatment was discon-
tinued in 27 cases because of progressive disease,  and in 
6 cases because of deterioration of the patient’s general 
condition though disease progression was not con-
firmed.  Two patients underwent conversion surgery 
and radiotherapy,  2 discontinued treatment because of 
AEs,  and 2 were transferred to supportive care at the 
patient’s request.  Treatment was ongoing in 4 cases at 
the time of writing (March 2020).
Of the 39 patients who stopped the regimen,  29 
cases (74.4%) received third-line therapy.  Twenty 
patients received nivolumab treatment; 1 received 
trifluridine-tipiracil (TAS-102); 1 received irinotecan 
(CPT-11); 3 received radiotherapy; and 2 underwent 
conversion surgery.  In 2 cases,  nab-PTX treatment was 
interrupted because of nab-PTX-related AEs,  although 
RAM treatment was continued.
Ten patients could not receive subsequent treatment.  




















　not performed 22 (51.2%)





　S-1 + cisplatin 7 (16.3%)
　S-1 + oxaliplatin 17 (39.5%)
　S-1 + docetaxel 5 (11.6%)
　capecitabine + oxaliplatin 7 (16.3%)
　capecitabine + oxaliplatin + trastuzumab 2 (4.7%)
　FOLFOX 1 (2.3%)
Table 2　 Result in our institution
Patients (N=43)
Median PFS 114 days
Median OS 297 days
ORR 32.4%
DCR 70.2%
Median total cycles (range) 3 cycles (1-11 cycles)
Relative dose intensity (range)
　nab-PTX 59.4% (25.9-100.0%)
　RAM 80.2% (14.3-100.0%)
Total dose (range,  mg/patient)
　nab-PTX 1041.0 (100-2350)
　RAM 3724.4 (250-8600)
Transition rate to 1st post-treatment (%) 74.4%





　RAM monotherapy 2 (4.7%)
　Conversion surgery 2 (4.7%)
　Radiotherapy 3 (7.0%)
　None 10 (23.3%)





　RAM monotherapy 1 (2.3%)
　None 27 (62.8%)
　Ongoing RAM+nab-PTX 4 (9.3%)
　Ongoing 1st post-treatment 1 (2.3%)
Reason of regimen stop
　Progressive disease 27 (62.8%)
　Adverse event 2 (4.7%)
　General Condition 6 (14.0%)
　Intervention Treatment
　(surgery,  radiotherapy) 2 (4.7%)
　Patientʼs intension 2 (4.7%)
　Ongoing RAM+nab-PTX 4 (9.3%)
Of these,  one patient died of another disease,  and the 
others could not receive this regimen for more than two 
cycles.
At the time of writing,  third-line treatment was 
ongoing in one case,  and one case showed no recur-
rence after conversion surgery.  Of the 27 patients who 
failed third-line therapy,  11 (40.7%) received subse-
quent therapy.  These regimens are shown in Table 2.
Discussion
The second-line chemotherapy regimen recom-
mended in the 2018 Japanese gastric cancer treatment 
guidelines (5th edition) [2] is a RAM plus weekly 
sb-PTX regimen,  while the RAM plus weekly nab-PTX 
regimen is recommended conditionally.
The sb-PTX regime requires premedication because 
of the inclusion of polyethoxylated castor oil and 
hydrated ethanol as solvents.  Because patients who 
receive sb-PTX are not able to drive due to the premed-
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Fig. 1　 Kaplan-Meier plot showing progression-free survival (A) and overall survival (B).
Table 3　 Adverse events in our institution
Patients (N=43)
Grage 1-2 Grade 3 Grade 4 Grade 5
Haemotological events
　Leucopenia 13 (30.2%) 13 (30.2%) 0 0
　Neutropenia 7 (16.3%) 9 (20.9%) 14 (32.6%) 0
　Anemia 19 (44.2%) 2 (4.7%) 0 0
　Thrombopenia 4 (9.3%) 0 0 0
　Febrile neutropenia 0 0 1 (2.3%) 0
Non-haemotological events 0 0 0 0
　Bleeding 6 0 0 0
　Proteinuria 13 (30.2%) 1 (2.3%) 0 0
　Hypertension 7 (16.3%) 0 0 0
　Infusion reaction 0 0 0 0
　Peripheral neuropathy 20 (46.5%) 0 0 0
　Vomitting 6 (14.0%) 0 0 0
　Appetite loss 15 (34.9%) 4 (9.3%) 0 0
　Diarrehea 11 (25.6%) 0 0 0
　Alopecia 14 (32.6%) 0 0 0
ication and alcohol,  the nab-PTX regimen is more use-
ful for patients attending the hospital from home,  espe-
cially in the countryside.  Additionally,  nab-PTX 
reduces the risk of polyethoxylated castor oil-associated 
hypersensitivity reactions,  and the administration time 
of nab-PTX is shorter than that of sb-PTX.  Thus,  nab-
PTX helps to mitigate the congestion of the outpatient 
chemotherapy facility.  Accordingly,  RAM+nab-PTX 
has been in use at our hospital as a standard treatment 
since 2018.
Although the non-inferiority of weekly nab-PTX 
compared to weekly sb-PTX has been confirmed 
[10 , 11],  there are insufficient practical data regarding 
the use of RAM plus weekly nab-PTX.  Here,  we retro-
spectively analyzed the efficacy and safety of RAM plus 
weekly nab-PTX at our institution.  As this study is both 
retrospective and a single-center analysis,  it may have 
some bias.
At our institution,  the ORR,  DCR,  and PFS were 
32.4%,  72.2%,  and 3.8 months,  respectively,  all of 
which are lower than those reported in a previously 
reported phase II trial of RAM+nab-PTX (54.8%,  
92.9%,  and 7.6 months,  respectively) [10].  However,  
≥ grade 3 neutropenia occurred in 53.5% of cases in the 
present study,  which was also lower than reported in 
the phase II trial (76.7%).  Although PFS was shorter 
than that reported in the phase II trial,  the RDIs of nab-
PTX and RAM at our institution were 59.4% and 
80.2%,  respectively,  which are similar to those reported 
in the phase II trial (61.8% and 87.6%,  respectively) 
[10].
The discrepancies of these results may be caused by 
the fact that 20.9% of the patients included in the pres-
ent study had an ECOG-PS of 2,  and some were near to 
having an ECOG-PS of 3.  The RAM+nab-PTX regimen 
was administered even to patients with a relatively poor 
ECOG-PS,  given the low occurrence of non-hemato-
logical AEs.  As patients with a poorer ECOG-PS were 
more likely to have relatively progressive cancer,  this 
may have led to the comparatively worse ORR,  DCR,  
and PFS values in our study.
Although the patient characteristics and PFS were 
worse in the present study,  OS was 9.9 months,  which 
is longer than that reported in a RAM plus sb-PTX 
phase III trial (RAINBOW trial,  9.6 months) [7].  The 
OS of the RAM+nab-PTX trial was not reported.  OS 
may be affected by changes made to the regimen 
according to the attending doctor’s diagnosis before CT,  
and the use of new reagents such as nivolumab or TAS-
102 [12 , 13].  Post-regimen analysis suggests that regi-
men changes in the early phase may prolong the prog-
nosis of patients with advanced gastric cancer,  and this 
approach may shorten PFS.
Several reports have suggested the efficacy of nab-
PTX for peritoneal metastasis or ascites [14-16],  
though these were negative prognostic factors in the 
RAM plus sb-PTX trial [7].  In the present study,  
reduced massive pleural effusion or reduced ascites 
were found in 4 of 9 cases (44.4%).  The fact that this 
percentage is higher than that of the ORR in our study 
(32.4%) suggests that nab-PTX is effective in treating 
ascites.
Although the frequency of ≥ grade 3 neutropenia 
was 53.5%,  febrile neutropenia occurred in only one 
case (2.3%).  The occurrence of these AEs was lower 
than that reported in clinical trials (76.7% and 4.7%,  
respectively,  RAM plus nab-PTX,  JapicCTI-153088;  
40.7% and 3.1%,  respectively,  RAM plus sb-PTX,  
RAINBOW),  and to the best of our knowledge,  no 
other critical AEs have been reported [7 , 10].  Therefore,  
regardless of differences in the characteristics of patients 
in trials and in real clinical practice,  RAM+nab-PTX 
appears to be safe.
In conclusion,  RAM+nab-PTX combination ther-
apy demonstrated manageable toxicity even in patients 
who were elderly or had an ECOG-PS of 2,  as well as 
favourable efficacy,  especially for disseminated gastric 
cancer.  This treatment is especially useful in commu-
nity hospital settings,  given its relatively shorter dura-
tion of administration and the fact that patients are able 
to drive themselves to and from the hospital.
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